SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (date of earliest event reported): February 20, 2007
Corgenix Medical Corporation
(Exact Name of registrant as specified in its charter)
Nevada |
| 000-24541 |
| 93-1223466 |
(State or other jurisdiction |
| (Commission File Number) |
| (I.R.S. Employer |
11575 Main Street
Suite 400
Broomfield, Colorado 80020
(Address, including zip code, of principal executive offices)
(303) 457-4345
(Registrant’s telephone number including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting Material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 8.01 Other Events
On February 20, 2007, BIOSAFE Laboratories, Inc. filed an answer and counterclaim in the United States District Court for the District of Colorado in response to a complaint filed by Corgenix Medical Corporation (the “Company”) on January 4, 2007. All claims and counterclaims in this matter stem from a non-binding Letter of Intent between the Company and BIOSAFE dated September 12, 2006. No settlement discussions are currently underway, and it is not possible to predict the ultimate outcome of the matter.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CORGENIX MEDICAL CORPORATION | ||
|
|
|
Date: February 21, 2007 | By: | /s/ Douglass T. Simpson |
|
| Douglass T. Simpson |
|
| President and Chief Executive Officer |
2
